These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 17353914)
1. Point-of-care PSA testing: an evaluation of PSAwatch. Karim O; Rao A; Emberton M; Cochrane D; Partridge M; Edwards P; Walker I; Davidson I Prostate Cancer Prostatic Dis; 2007; 10(3):270-3. PubMed ID: 17353914 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer. Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094 [TBL] [Abstract][Full Text] [Related]
3. Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. Azzouzi AR; Larre S; Cormier L; Roupret M; Valeri A; Mangin P; Berthon P; Villette JM; Fiet J; Cussenot O BJU Int; 2007 Apr; 99(4):762-4. PubMed ID: 17233806 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Miano R; Mele GO; Germani S; Bove P; Sansalone S; Pugliese PF; Micali F Prostate Cancer Prostatic Dis; 2005; 8(3):219-23. PubMed ID: 15897915 [TBL] [Abstract][Full Text] [Related]
5. Trends in prostate-specific antigen testing from 1995 through 2004. Farwell WR; Linder JA; Jha AK Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173 [TBL] [Abstract][Full Text] [Related]
6. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen. Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203 [TBL] [Abstract][Full Text] [Related]
7. The relationship between prostate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men. Hevey D; Pertl M; Thomas K; Maher L; Chuinneagáin SN; Craig A Patient Educ Couns; 2009 Feb; 74(2):244-9. PubMed ID: 18848753 [TBL] [Abstract][Full Text] [Related]
8. Obesity and screening PSA levels among men undergoing an annual physical exam. Rundle A; Neugut AI Prostate; 2008 Mar; 68(4):373-80. PubMed ID: 18189231 [TBL] [Abstract][Full Text] [Related]
9. PSA screening. Cohen S; Schiff S; Kelty P Med Health R I; 2005 Mar; 88(3):90-1. PubMed ID: 15915782 [No Abstract] [Full Text] [Related]
10. Point-of-care fluorescence immunoassay for prostate specific antigen. Oh SW; Kim YM; Kim HJ; Kim SJ; Cho JS; Choi EY Clin Chim Acta; 2009 Aug; 406(1-2):18-22. PubMed ID: 19393638 [TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen best practice statement: 2009 update. Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717 [TBL] [Abstract][Full Text] [Related]
13. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722 [TBL] [Abstract][Full Text] [Related]
14. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men]. Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292 [No Abstract] [Full Text] [Related]
15. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331 [TBL] [Abstract][Full Text] [Related]
16. Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492 [TBL] [Abstract][Full Text] [Related]
17. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425 [TBL] [Abstract][Full Text] [Related]
18. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305 [TBL] [Abstract][Full Text] [Related]
19. Is the PSA test useless? Kirby R; Moul JW Prostate Cancer Prostatic Dis; 2004; 7(4):271-2. PubMed ID: 15592438 [No Abstract] [Full Text] [Related]
20. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Grubb RL; Black A; Izmirlian G; Hickey TP; Pinsky PF; Mabie JE; Riley TL; Ragard LR; Prorok PC; Berg CD; Crawford ED; Church TR; Andriole GL; Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):748-51. PubMed ID: 19258472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]